Coeptis Therapeutics Holdings Inc

Change company Symbol lookup

Select an option...

COEP Coeptis Therapeutics Holdings Inc

FBK FB Financial Corp

DLY DoubleLine Yield Opportunities Fund

APTO Aptose Biosciences Inc

JQC Nuveen Credit Strategies Income Fund

GAB Gabelli Equity Trust

AMSF Amerisafe Inc

CLNE Clean Energy Fuels Corp

HUM Humana Inc

GAIA Gaia Inc

Go

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is focused on developing cell therapy platforms for cancer. The Company's product portfolio and rights are highlighted by a universal, multi-antigen chimeric antigen receptor (CAR)-T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK) and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the Company is developing with VyGen-Bio and medical researchers at the Karolinska Institute. Its CAR therapy is a treatment for cancer in which a patient's T cells (a type of immune cell) are genetically engineered to recognize cancer cells to target and destroy them. Its CAR T therapies are revolutionizing the treatment of many blood cancers, including B cell leukemias and lymphomas by targeting specific proteins found in these cancers.